The current stock price of ISRG is 561.61 USD. In the past month the price increased by 2.76%. In the past year, price increased by 2.51%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.67 | 222.97B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.84 | 143.55B | ||
| SYK | STRYKER CORP | 27.96 | 140.79B | ||
| IDXX | IDEXX LABORATORIES INC | 57.57 | 58.07B | ||
| BDX | BECTON DICKINSON AND CO | 13.36 | 55.24B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| RMD | RESMED INC | 25.33 | 36.59B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.66 | 34.82B | ||
| DXCM | DEXCOM INC | 32.38 | 23.62B | ||
| PODD | INSULET CORP | 72.47 | 23.30B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.39 | 18.26B | ||
| HOLX | HOLOGIC INC | 17.41 | 16.54B |
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 15,638 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
INTUITIVE SURGICAL INC
1020 Kifer Road
Sunnyvale CALIFORNIA 94086 US
CEO: Gary S. Guthart
Employees: 15638
Phone: 14085232100
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 15,638 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
The current stock price of ISRG is 561.61 USD. The price increased by 1.7% in the last trading session.
ISRG does not pay a dividend.
ISRG has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
INTUITIVE SURGICAL INC (ISRG) has a market capitalization of 201.33B USD. This makes ISRG a Mega Cap stock.
INTUITIVE SURGICAL INC (ISRG) will report earnings on 2026-01-21, after the market close.
The outstanding short interest for INTUITIVE SURGICAL INC (ISRG) is 1.92% of its float.
ChartMill assigns a technical rating of 8 / 10 to ISRG. When comparing the yearly performance of all stocks, ISRG is one of the better performing stocks in the market, outperforming 79.2% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to ISRG. Both the health and profitability get an excellent rating, making ISRG a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months ISRG reported a non-GAAP Earnings per Share(EPS) of 8.61. The EPS increased by 28.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.58% | ||
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| Debt/Equity | 0 |
41 analysts have analysed ISRG and the average price target is 610.08 USD. This implies a price increase of 8.63% is expected in the next year compared to the current price of 561.61.
For the next year, analysts expect an EPS growth of 19.93% and a revenue growth 21.17% for ISRG